It turns out that Covid-19 vaccines are like the old joke about buses. You wait for ages and then three turn up at the same time. Over the last month, we have seen stunning results from Pfizer, Moderna and Oxford-AstraZeneca. Each vaccine is slightly different, in terms of effectiveness, and how quickly it can be rolled out, but there is now no question that we are close to a mass vaccination programme that should bring the virus under control. Six months ago plenty of experts were arguing it would take five years or more to get a working shot. In fact, it has been done in less than a year.
Don’t throw sand in the wheels
But there’s a problem. Now that we are close to a vaccine, the arguments are starting about who gets it, when, and on what terms. There are complaints about the potential for the drugs companies to make excess profits. And countries such as South Africa and India are calling on the World Health Organisation to suspend patent protection on the vaccines so that they can be manufactured by anyone at cost.
It is easy to understand the arguments for that. A Covid-19 vaccine is needed around the world, and some countries might struggle to afford it. It doesn’t make any sense just to vaccinate the richer countries. If the virus is still rampant around the world it will just come back in more virulent forms. The trouble is, suspending patents, and stopping drug companies from making money from the vaccine, would be a disaster, not just for the shareholders in those businesses, but for the whole world.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Why? Getting a vaccine in less than a year is a huge achievement, and one that has cost vast sums of money, much of it privately funded. If the only reward for that is to have the patent rights taken away, then will the companies make the same kind of effort the next time there is a global epidemic?
Second, some exciting new technologies are emerging. The genetics-based vaccines that seem to be working against Covid-19 can not only be developed far more quickly than traditional shots but may also work against many other conditions as well. We already have vaccines that can work against some form of cancers. Over the next decade the technology that has advanced at rapid speed in this crisis may well turn out to be just as good at dealing with other forms of cancer, dementia, Alzheimer’s, and a whole range of hard-to-treat diseases. But if we don’t allow companies patent protection on the technologies they are developing, then that is far less likely to happen – and we will all be worse off for that.
Whatever the profits, it’s a bargain
Finally, it is immoral. Private companies have done the work on a vaccine, they have risked their own money, and they have devoted time and resources to solving a global crisis. They deserve to be rewarded for that. So do their shareholders. If we start taking one form of property away from companies, then where do we stop? In truth, we should probably reward vaccine makers more than we are right now – for example by extending the patent protection from 20 to 30 years. Given the vast cost of the epidemic in terms of locked-down economies, closed businesses and schools, lost jobs, and broken families, if anything we are paying too little for the science that will get us out of the mess, not too much.
There are far better ways of dealing with the issue of global access. The sums of money are not huge, especially when set against the scale of the challenge. Take a relatively poor country such as South Africa, with one of the worst outbreaks on the continent. Even with Moderna’s vaccine, at £30 a shot, the most expensive so far, it would only cost £1.5bn to vaccinate the entire country. If the government can’t raise that, then aid budgets, and charities, could probably step in and fill the gap. If the poorest 20% of the global population needs help paying for the vaccine, then the G20, representing the richest countries in the world, could easily step in with an emergency funding programme. That way we still get the vaccine out around the world, and we also properly reward the companies that made it.
-
British Airways revamps Avios scheme bringing down flight prices to £1With the new Avios part-payments scheme you can now bag a British Airways flight for as little as £1
-
RBS to close a fifth of branchesRoyal Bank of Scotland plans to shut 18 branches across Scotland, resulting in the loss of 105 jobs. We have the full list of closures.
-
The industry at the heart of global technologyThe semiconductor industry powers key trends such as artificial intelligence, says Rupert Hargreaves
-
Three emerging Asian markets to invest inProfessional investor Chetan Sehgal of Templeton Emerging Markets Investment Trust tells us where he’d put his money
-
What to consider before investing in small-cap indexesSmall-cap index trackers show why your choice of benchmark can make a large difference to long-term returns
-
Why space investments are the way to go for investorsSpace investments will change our world beyond recognition, UK investors should take note
-
Time to tap into Africa’s mobile money boomFavourable demographics have put Africa on the path to growth when it comes to mobile money and digital banking
-
M&S is back in fashion: but how long can this success last?M&S has exceeded expectations in the past few years, but can it keep up the momentum?
-
The end of China’s boomLike the US, China too got fat on fake money. Now, China's doom is not far away.
-
Magic mushrooms — an investment boom or doom?Investing in these promising medical developments might see you embark on the trip of a lifetime.
